Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal...

Related Keywords

Quang Pham ,Matthew Szot ,Robert Blum ,Nasdaq ,Prnewswire Cadrenal Therapeutics Inc ,Lytham Partners ,Cadrenal Therapeutics Inc ,Panel Presentation ,Company Webcast ,Fast Track ,Lytham Partners Spring ,Cadrenal Therapeutics ,Nc ,